ABSTRACT

The present work converse the outline of Favipiravir for its effective role against the virus. The central drugs standard control organization granted accelerated approval to Glenmark pharmaceuticals to market Favipiravir in mild-to-moderate COVID-19 on June 19, 2020, for restricted use. It is the right time to take policy decision and frame guidelines on how to handle emergency approvals for medicinal products in grave situations such as the COVID19 pandemic in India. This paper gives the information about the complete drug profile of Favipiravir like structure, mechanism of action, kinetics, drug interactions, clinical trials data, analysis of drug and adverse effects. It has good antiviral activity, because of this it is extensively studied for its probable use in treatment for this corona virus. Favipiravir was first introduced in Japan in 2014 as a cure for influenza after the research on this medicine also revealed that it is a broad spectrum medicine and can be used in treatment of many viral diseases. Keywords: Favipiravir, COVID-19, SARS-CoV-2
Publication date: 01/12/2021

https://ijbpas.com/pdf/2021/December/MS_IJBPAS_2021_5738.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2021/10.12.5738